ABT - Abbott Laboratories

NYSE - NYSE Delayed Price. Currency in USD
70.08
+0.33 (+0.47%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close69.75
Open70.85
Bid69.00 x 800
Ask72.59 x 1000
Day's Range69.31 - 70.90
52 Week Range55.58 - 74.92
Volume8,392,377
Avg. Volume7,068,945
Market Cap123.084B
Beta (3Y Monthly)1.51
PE Ratio (TTM)141.01
EPS (TTM)0.50
Earnings DateJan 23, 2019
Forward Dividend & Yield1.28 (1.81%)
Ex-Dividend Date2019-01-14
1y Target Est79.58
Trade prices are not sourced from all markets
  • Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
    Zacks13 hours ago

    Abbott (ABT) Outpaces Stock Market Gains: What You Should Know

    Abbott (ABT) closed at $70.08 in the latest trading session, marking a +0.47% move from the prior day.

  • 5 Beaten-Down Medical Product Stocks to Rebound in 2019
    Zacks22 hours ago

    5 Beaten-Down Medical Product Stocks to Rebound in 2019

    As the Medical product industry is witnessing temporary sluggishness, a sneak peek into some possible outperformers in 2019 could be a great idea for investors.

  • Abbot Labs to Rise
    GuruFocus.com2 days ago

    Abbot Labs to Rise

    Abbott Laboratories (ABT) fell 1.97% to $70.73 per share on the New York Stock Exchange Friday after the company's announcement of a 14% cash quarterly dividend hike to 32 cents from 28 cents. The increase, which will take time to be processed by the stock market, will produce upside in the share price of the Lake Bluff, Illinois-headquartered healthcare company. Abbott Labs has climbed 24% for the 52 weeks through Friday, outperforming the S&P 500 index by more than 22%.

  • MBIO: Mustang: A Steed on the Fast Track
    Zacks Small Cap Research2 days ago

    MBIO: Mustang: A Steed on the Fast Track

    Recognized as an innovator in the chimeric antigen receptor (CAR) engineered T cell (CAR-T) space, Mustang Bio (MBIO) has focused its efforts on immuno-oncology indications since its inception in 2015. The company targets both liquid and solid tumors using CAR-T and has built a facility to supply manufactured cell products for clinical trials and commercial production. Despite this emphasis and progress with MB-102, Mustang acquired an existing gene therapy program with promising clinical data and a clear path to registration via expedited pathways.

  • ACCESSWIRE2 days ago

    A Solution to the Nation's Current Opioid Overdose Epidemic and The World's Leading Cause of Disability

    HENDERSON, NV / ACCESSWIRE / December 17, 2018 / Low back pain is the leading cause of disability in the world and the second most cause of disability in the United States. Degenerative disc disease is one of the most common causes of back pain, affecting more than 3 million people in the US per year. Is estimated that the cost for back pain range from to "at least $50 billion per year" (American Chiropractic Association) to $86 billion per year (WebMD) and to more than $200 billion dollars per year (American Academy of Orthopaedic Surgeons).

  • PR Newswire2 days ago

    Abbott Hosts Conference Call for Fourth-Quarter Earnings

    ABBOTT PARK, Ill., Dec. 17, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) will announce its fourth-quarter 2018 financial results on Wednesday, Jan. 23, 2019 , before the market opens.  The announcement will ...

  • 5 Biggest Medtech Stocks -- Are They Buys?
    Motley Fool5 days ago

    5 Biggest Medtech Stocks -- Are They Buys?

    These medtech giants rule the industry. But are any of them great picks for long-term investors?

  • PR Newswire5 days ago

    Abbott Raises Quarterly Dividend 14%, Increasing Payouts for 47 Straight Years

    ABBOTT PARK, Ill., Dec. 14, 2018 /PRNewswire/ -- The board of directors of Abbott (NYSE: ABT) today increased the company's quarterly common dividend to 32 cents per share, marking a 14 percent increase. ...

  • Do Analysts See Any Upside for DaVita Stock?
    Market Realist5 days ago

    Do Analysts See Any Upside for DaVita Stock?

    Of the ten analysts covering DaVita (DVA), five have given it “buy” or higher ratings, four have given it “holds,” and one has given it a “sell.”

  • Understanding Abbott Laboratories’ Operational Performance
    Market Realist6 days ago

    Understanding Abbott Laboratories’ Operational Performance

    In the latest quarter, Abbott Laboratories’ (ABT) selling, general, and administrative expenses rose YoY (year-over-year) to $2.38 billion from $2.11 billion due to its Alere acquisition and expenditure for expanding the company’s different businesses. Meanwhile, its R&D (research and development) expenses rose YoY to $574.0 million from $568.0 million due to the Alere acquisition and increased cardiovascular and neuromodulation spending. It is expected to have R&D expenses of $2.25 billion and $2.36 billion, respectively, in fiscal 2018 and fiscal 2019, compared with $1. ...

  • Health Check: How Abbott Laboratories is Positioned
    Market Realist6 days ago

    Health Check: How Abbott Laboratories is Positioned

    Abbott Laboratories (ABT) offers products in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Cardiovascular and Neuromodulation Products. In this series, we’ll explore Abbott’s financials and valuation, and analysts’ views on its stock.

  • Abbott Laboratories’ Gross Margin Trends
    Market Realist6 days ago

    Abbott Laboratories’ Gross Margin Trends

    In fiscal 2018 and fiscal 2019, Abbott Laboratories (ABT) is expected to generate revenue of $30.66 billion and $32.21 billion, respectively, compared with revenue of $27.39 billion in fiscal 2017. Meanwhile, peers Biogen (BIIB), Johnson & Johnson (JNJ), and Pfizer (PFE) are expected to have revenue of $13.31 billion, $81.35 billion, and $53.59 billion, respectively, in fiscal 2018. Abbott’s cash per share is $4.20, while Biogen, Johnson & Johnson, and Pfizer have cash per share of $21.31, $7.20, and $2.90, respectively.

  • Financial Times6 days ago

    [$$] Number of Britons linked to far-right extremism soars

    in connection with far-right extremism has risen by more than a third during the past year, new figures show. for far-right activity rose by 36 per cent in the year to March 2018, accounting for 18 per cent of all of those admitted to the programme, according to Home Office statistics. Referrals concerning individuals thought to be at risk of Islamist extremism fell by 14 per cent, but still make up the highest proportion of all programme admissions at 44 per cent.

  • Abbott (ABT) Outpaces Stock Market Gains: What You Should Know
    Zacks7 days ago

    Abbott (ABT) Outpaces Stock Market Gains: What You Should Know

    Abbott (ABT) closed the most recent trading day at $72.53, moving +0.96% from the previous trading session.

  • InvestorPlace7 days ago

    5 Pharma Stocks That Could Cure Ailing Portfolios in 2019

    The pharmaceutical sector delivers two benefits that appeal to investors: reasonable P/E ratios and growth catalysts. Many pharma stocks have suffered as of late. Some have key drugs facing patent expirations.

  • A Look at Medtronic’s Earnings Trends and Guidance for Fiscal 2019
    Market Realist7 days ago

    A Look at Medtronic’s Earnings Trends and Guidance for Fiscal 2019

    Medtronic (MDT) reported net income of $1.1 billion in the second quarter of fiscal 2019 compared to $2.0 billion in the second quarter of fiscal 2018. Medtronic’s net income in the first half of fiscal 2019 totaled $2.2 billion compared to $3.0 billion in the same period the prior year. Wall Street analysts anticipate that Medtronic is expected to report net income of $1.25 billion in the third quarter of fiscal 2019.

  • How Medtronic’s Revenues and Expenses Are Trending
    Market Realist7 days ago

    How Medtronic’s Revenues and Expenses Are Trending

    Medtronic (MDT) reported net revenues of $7.5 billion in the second quarter of fiscal 2019 compared to $7.1 billion in the second quarter of fiscal 2018, reflecting 6% YoY growth.

  • How Wall Street Analysts View Medtronic in December
    Market Realist7 days ago

    How Wall Street Analysts View Medtronic in December

    In November, Medtronic announced that the company would acquire Nutrino Health, a company that specializes in nutrition associated data services, analytics, and technologies. Medtronic’s diabetes segment is expected to improve significantly with the acquisition of Nutrino Health. The acquisition of Nutrino Health will bring together Nutrino Health’s robust food database, expertise in nutrition science and food analysis systems, and Medtronic’s innovative diabetes management resources.

  • TheStreet.com8 days ago

    Shire, Abbott Labs May Pace Healthcare Stocks in 2019

    Shire is a pharmaceutical company, with a wide range of products approved for use around the world. Some of the more familiar drugs the company produces include Adderall, prescribed for adult ADD, and Pentasa, used to treat Crohn's and other inflammatory bowel diseases. The company possesses both strength and weakness, and both are evident in the most recent quarterly report.

  • Will GE’s Healthcare Unit Spin-Off Increase Shareholder Wealth?
    Market Realist8 days ago

    Will GE’s Healthcare Unit Spin-Off Increase Shareholder Wealth?

    Why Has General Electric Stock Struggled in 2018? The Healthcare segment is the fourth-largest contributor to General Electric’s total revenues. As part of the company’s major restructuring plan in June, General Electric intends to spin off the segment and turn it into a standalone entity.

  • How Much Upside Do Analysts Expect in Endo Stock?
    Market Realist8 days ago

    How Much Upside Do Analysts Expect in Endo Stock?

    In December 2018, of the total 16 analysts covering Endo International (ENDP), five analysts have given Endo stock a “buy” or higher rating and 11 analysts have given it a “hold” rating. The mean rating for Endo International stock is 2.5 with a target price of $17.04, implying an upside potential of 47.3% over Endo International’s closing price of $11.57 on December 7, 2018.

  • PR Newswire8 days ago

    Abbott to Present at J.P. Morgan Healthcare Conference

    ABBOTT PARK, Ill., Dec. 11, 2018 /PRNewswire/ -- Abbott (NYSE: ABT) will present at the 37 th Annual J.P. Morgan Healthcare Conference on Tuesday, Jan. 8, 2019 . Brian Yoor , executive vice president of ...

  • What Endo International’s Bottom Line Trend Indicates
    Market Realist8 days ago

    What Endo International’s Bottom Line Trend Indicates

    How's Endo International Positioned in December? Endo International (ENDP) incurred net interest expenses of $131.85 million in the third quarter of 2018 as compared with $127.52 million in the year-ago period. Endo International’s net loss per share was $0.43 in the third quarter of 2017.

  • Generic-drug stocks slammed by report of expanded price-fixing probe
    MarketWatch8 days ago

    Generic-drug stocks slammed by report of expanded price-fixing probe

    Shares of generic drug makers fell sharply Monday, after a Washington Post report that an antitrust lawsuit brought by states over two drugs in 2016 has expanded into a major probe of alleged price-fixing across the industry.